ArticleFrontiers in oncology2025

Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer.

Jean Cabon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.